Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Feb, 2016 | Pages:
45 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Restless Legs Syndrome - Pipeline Review, H1 2016 Summary
Global Markets Direct's, 'Restless Legs Syndrome - Pipeline Review, H1 2016', provides an overview of the Restless Legs Syndrome pipeline landscape. The report provides comprehensive information on the therapeutics under development for Restless Legs Syndrome, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Restless Legs Syndrome and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape of Restless Legs Syndrome - The report reviews pipeline therapeutics for Restless Legs Syndrome by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Restless Legs Syndrome therapeutics and enlists all their major and minor projects - The report assesses Restless Legs Syndrome therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Restless Legs Syndrome Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Restless Legs Syndrome - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Restless Legs Syndrome pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Restless Legs Syndrome Overview 6 Therapeutics Development 7 Pipeline Products for Restless Legs Syndrome - Overview 7 Restless Legs Syndrome - Therapeutics under Development by Companies 8 Restless Legs Syndrome - Pipeline Products Glance 9 Late Stage Products 9 Clinical Stage Products 10 Early Stage Products 11 Restless Legs Syndrome - Products under Development by Companies 12 Restless Legs Syndrome - Companies Involved in Therapeutics Development 13 Alexza Pharmaceuticals, Inc. 13 Hisamitsu Pharmaceutical Co., Inc. 14 Ligand Pharmaceuticals, Inc. 15 Mundipharma International Ltd 16 Omeros Corporation 17 Vifor Pharma AG 18 Restless Legs Syndrome - Therapeutics Assessment 19 Assessment by Monotherapy Products 19 Assessment by Combination Products 20 Assessment by Target 21 Assessment by Mechanism of Action 23 Assessment by Route of Administration 25 Assessment by Molecule Type 27 Drug Profiles 28 (naloxone hydrochloride + oxycodone hydrochloride) ER - Drug Profile 28 Product Description 28 Mechanism of Action 28 R&D Progress 28 aplindore fumarate - Drug Profile 30 Product Description 30 Mechanism of Action 30 R&D Progress 30 AZ-008 - Drug Profile 31 Product Description 31 Mechanism of Action 31 R&D Progress 31 ferric carboxymaltose - Drug Profile 32 Product Description 32 Mechanism of Action 32 R&D Progress 32 OMS-527 - Drug Profile 34 Product Description 34 Mechanism of Action 34 R&D Progress 34 ropinirole hydrochloride - Drug Profile 35 Product Description 35 Mechanism of Action 35 R&D Progress 35 Restless Legs Syndrome - Recent Pipeline Updates 36 Restless Legs Syndrome - Dormant Projects 38 Restless Legs Syndrome - Discontinued Products 39 Restless Legs Syndrome - Product Development Milestones 40 Featured News & Press Releases 40 May 29, 2015: Napp receives approval from MHRA to prescribe Targinact (oxycodone/naloxone) for the treatment of Restless Legs 40 Oct 24, 2014: Mundipharma receives Positive CHMP Opinion for Targin (oxycodone / naloxone) for the treatment of Restless Legs Syndrome 41 Jan 07, 2014: Mundipharma receives positive European Commission decision on Targin (oxycodone/naloxone) for the treatment of Restless Legs Syndrome 41 Nov 19, 2013: New data show efficacy of prolonged release TARGIN (oxycodone / naloxone) in the treatment of severe restless legs syndrome 42 Oct 16, 2008: Neurogen Announces Positive Top-Line Results From Two Phase II Trials For Aplindore In Restless Legs Syndrome And Parkinson's Disease 43 Appendix 44 Methodology 44 Coverage 44 Secondary Research 44 Primary Research 44 Expert Panel Validation 44 Contact Us 44 Disclaimer 45
List of Tables
Number of Products under Development for Restless Legs Syndrome, H1 2016 7 Number of Products under Development by Companies, H1 2016 8 Comparative Analysis by Late Stage Development, H1 2016 9 Comparative Analysis by Clinical Stage Development, H1 2016 10 Comparative Analysis by Early Stage Development, H1 2016 11 Products under Development by Companies, H1 2016 12 Restless Legs Syndrome - Pipeline by Alexza Pharmaceuticals, Inc., H1 2016 13 Restless Legs Syndrome - Pipeline by Hisamitsu Pharmaceutical Co., Inc., H1 2016 14 Restless Legs Syndrome - Pipeline by Ligand Pharmaceuticals, Inc., H1 2016 15 Restless Legs Syndrome - Pipeline by Mundipharma International Ltd, H1 2016 16 Restless Legs Syndrome - Pipeline by Omeros Corporation, H1 2016 17 Restless Legs Syndrome - Pipeline by Vifor Pharma AG, H1 2016 18 Assessment by Monotherapy Products, H1 2016 19 Assessment by Combination Products, H1 2016 20 Number of Products by Stage and Target, H1 2016 22 Number of Products by Stage and Mechanism of Action, H1 2016 24 Number of Products by Stage and Route of Administration, H1 2016 26 Number of Products by Stage and Molecule Type, H1 2016 27 Restless Legs Syndrome Therapeutics - Recent Pipeline Updates, H1 2016 36 Restless Legs Syndrome - Dormant Projects, H1 2016 38 Restless Legs Syndrome - Discontinued Products, H1 2016 39
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
